Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 818 posts found.

Novartis shares new data about Fabhalta for IgAN treatment

April 16, 2024
Research and Development Fabhalta, IgAN, Nephrology, Novartis, nephropathy

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN trial of Fabhalta (iptacopan), an …

News
chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

March 5, 2024
Musculo-skeletal disorder, Novartis, Zolgensma, sma, spinal muscular atrophy

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma (onasmenogene abeparvovec), for the treatment …

News

Novartis to acquire MorphoSys AG for €2.7bn

February 6, 2024
Business Services Novartis, Pharmacy, acquisition, morphosys

Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, or €68 per share. The …

News

Calypso Biotech to be acquired by Novartis for $250m

January 8, 2024
Business Services Calypso Biotech, Immunology, Novartis, acquisition

Calypso Biotech has announced that it has entered into an agreement to be acquired by Novartis. The company’s shareholders will …

News

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023
Medical Communications FDA, Fabhalta, Haematology, Novartis, PNH

Novartis has announced that the US Food and Drug Administration has approved Fabhalta (iptacopan) as the first oral monotherapy for …

News

Ionis and Novartis partner for CVD treatment programme

August 4, 2023
Business Services Cardiology, Ionis Pharmaceuticals, License Agreement, Novartis, cvd

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement with Novartis, aiming to discover, …

News
kidney

Novartis acquires Chinook Therapeutics for $3.5bn

June 12, 2023
Mergers and Acquisitions Chinook Therapeutics, Nephrology, Novartis, kidney disease, pharma

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based biopharmaceutical company Chinook Therapeutics for …

News

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

April 27, 2023
Business Services CHMP, Cosentyx, Dermatology, Novartis

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European …

News
Press release
pm_society

AstraZeneca, Klarify, and Novartis Gene Therapies top Digital Awards leaderboard

September 20, 2021
Sales and Marketing AstraZeneca, Klarify, Novartis, PM Society Awards, havas life medicom

Pharmaceutical companies AstraZeneca, Klarify, and Novartis Gene Therapies all received two gold awards at the 12th PM Society Digital Awards …

News

Novartis announce digital collaboration with HPE

June 24, 2021
AI, HPE, Novartis

Swiss pharma company, Novartis, has announced a collaboration with Hewlett Packard Enterprise (HPE), to accelerate its use of data and …

News

NICE recommends two new treatments for inflammatory arthritis

June 18, 2021
Medical Communications Eli Lilly, NICE, Novartis

NICE has recommended two new treatments for axial spondyloarthritis, an underdiagnosed and debilitating type of inflammatory arthritis. Ixekizumab (also known …

News

Novartis report longest median OS in breast cancer study

June 3, 2021
Novartis, breast cancer, trials

Novartis has announced updated median overall survival (OS) results for Kisqali (ribociclib), in combination with fulvestrant, in postmenopausal women with …

News

Novartis eye treatment for diabetics shows positive results in Phase III trial

May 4, 2021
Manufacturing and Production DME, Novartis, diabetic macular edema, macular edema, pharma, pharma news

Novartis’ Beovu treatment for diabetic macular edema (DME) – an eye condition that can cause blindness – has shown positive …

News

Novartis multiple sclerosis treatment recommended by NICE

April 20, 2021
Manufacturing and Production NICE, Novartis, multiple sclerosis, pharma, pharma news

NICE have recommenced Novartis’ ofatumumab (Kesimpta) for the treatment of relapsing remitting MS (RRMS) in adult patients for use on …

News

Novartis signs capacity and technology transfer agreement for Roche drug

April 15, 2021
Novartis, Roche, production

Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024